Posts Tagged: NIH


Senate passes 21st Century Cures Act, President Obama expected to quickly sign bill into law

Earlier today, by a vote of 94 to 5, the United States Senate overwhelmingly passed the 21st Century Cures Act. Having passed in the House, the Cures Act now …
By Gene Quinn
4 years ago 6

Property Rights Key to Bayh-Dole Act’s Success

The focus of the political advocates pushing march-in may be lower drug costs. But the long-term costs of ripping apart IP rights are far higher and more …
By James Edwards
4 years ago 5

Toxic algal blooms of today could become the biofuels, fertilizers and antibiotics of tomorrow

At the time of an NIH study in 2011, algae-based biofuel production costs using conventional technologies were anywhere from $300 USD to $2,600 USD per barrel, much higher than the …
By Steve Brachmann
4 years ago 2

The superbugs are here, but where are we?

Superbugs have powerful friends in high places. SCOTUS’s patent eligibility criteria emanating from Mayo/Alice’s mysterious “laws of nature” and credible reports of unremitting turndowns …
By Chris Gallagher
4 years ago 6

NIH Director Collins Stands Up to the March in Mob

The problem with this theory is that the Bayh-Dole Act does not provide agencies the authority to regulate product prices. The law allows universities and contractors to …
By Joseph Allen
4 years ago 0

Blue Ribbon Panel of Advisors Announced for Biden Cancer Moonshot Initiative

Earlier this week the National Cancer Institute (NCI), which is part of the National Institutes of Health, announced a Blue Ribbon Panel of scientific experts, cancer leaders, …
By Gene Quinn
5 years ago 5

NIH Pressured to Misuse Bayh-Dole to Control Drug Prices

Secretary Burwell and Director Collins are facing formidable pressure to reinterpret the Bayh-Dole Act for the compulsory licensing of costly drugs arising from federally supported research. And …
By Joseph Allen
5 years ago 6

Winning the Patent Policy Wars

We're in the business of transforming early stage, publicly funded research into useful products. The odds against success are long as commercialization requires years of hard work, …
By Joseph Allen
5 years ago 2

British approval of embryonic gene editing research brings CRISPR-Cas9 into focus

England isn’t the only part of the world where embryonic gene editing research has been finding a foothold. In early 2015, researchers out of China published a …
By Steve Brachmann
5 years ago 0

Bayh-Dole Under March-in Assault: Can It Hold Out?

The new year was hardly underway before Representative Lloyd Doggett (D-TX) and 50 of his House colleagues sent a letter to Health and Human Services Secretary Sylvia Burwell …
By Joseph Allen
5 years ago 0

Around and Around We Go: The Drug Development Debate

Every once and a while we get a clear example of the gulf between those battling over important public policy issues and can understand why the public …
By Joseph Allen
6 years ago 4

Hunting Bayh-Dole Vampires

The government is funding basic research at universities, not drug development. Bayh-Dole allows schools to own resulting inventions and license them for commercialization. These discoveries are more …
By Joseph Allen
7 years ago 1

NIH Gets It Right: Bayh-Dole is not for Price Controls

The National Institutes of Health recently made its long anticipated ruling on a petition seeking to use the “march in” provisions of the Bayh-Dole Act as a …
By Joseph Allen
7 years ago 1

High Noon for Bayh-Dole

Senate Judiciary Committee Chairman Patrick Leahy (D-VT) asked NIH in a July 12 letter to force compulsory licensing of Myriad’s BRCA breast and ovarian cancer genetic test …
By Joseph Allen
7 years ago 3

Time to Take a Stand

If you’re paying attention at all, you must have noticed that there are forces out there who just don’t like what you do. Some say …
By Joseph Allen
8 years ago 6